Home
About us
News
Products
Innovation
CMO/CDMO Services
Contact
中文
undefined
Jiudian Hongyang's API Dexketoprofen Tromethamine Approved for Marketing
Recently, Jiudian Hongyang's API Dexketoprofen Tromethamine (Y20210000881) officially obtained the marketing approval from CDE, and its registration status was successfully transferred to "A".
28
2024
/
08
Jiudian Hongyang's API Prilocaine Obtains Marketing Approval
Recently, JiuDian HongYang's API Prilocaine (Y20220000870) has been officially approved by CDE, and its registration status has been successfully changed to "A".
Jiudian Pharmaceutical convey greetings to firefighters at Jinyang Fire Station on 1st August
On 1st August, Xun Xiaoyong, Minister of the Equipment Management Department of Jiudian Production Center, and Chen Shanshan, Deputy Minister of the Administration Department, visited the Jinyang Fire Station in Liuyang Economic Development Zone to express their highest respect and deep gratitude to the firefighters, and sent sincere blessings and condolences on behalf of the company.
02
Jiudian Pharmaceutical Production Center held a semi-annual meeting
On 26th July, JiuDian Production Center held a semi-annual working meeting with the theme of "Compliance Production, Collaboration and Pragmatism". The director of production center, Mr. Xiang Bo, the deputy director, Mr. Lu Shang, and all the middle-level managers attended the meeting.
30
07
Jiudian Hongyang held a farewell ceremony for retired employee
On 19th July, JiuDian HongYang Labor Union held a retirement farewell ceremony for Tan Liping, an employee of the Administration Department, with the theme of "Grateful for having you along the way", in which Wang Qianzhi, vice-chairman of JiuDian HongYang Labor Union, and representatives of the labor union attended the ceremony.
29
Jiudian Pharmaceutical exhibited at the 22nd CPHI China
From June 19th to 21st, the 22nd CPHI China was held in Shanghai, with more than 3,500 domestic and international exhibitors, displaying an area of 210,000 square meters and attracting more than 90,000 visitors from all over the world. Ms. Zhu Jiawen, Director of Business Cooperation Department of Jiudian Pharmaceutical, and Ms. Zeng Ling, Director of International Expansion Department of Jiudian Hongyang, led the team to participate in the exhibition.
25
06
’The API Empagliflozin Receives Marketing Authorization
Recently, the API Empagliflozin (Y20220001228) held by Jiudian HongYang has been officially approved by CDE and its registration status has been successfully changed to "A".
20
Tolterodine tartrate (Y20230000094) has been registered in CDE with the status of “A”
The API Tolterodine tartrate (Y20230000094) held by Jiudian HongYang, a wholly-owned subsidiary of Jiudian Pharmaceutical, has been registered in CDE with the status of “A” in June, 2024.
05
